"ACT has achieved results according to plan and has even observed evidence of engraftment of the transplanted stem cells in addition to visual acuity gain in the treated patients. ACT is so confident in their future that they have elected not to complete a reverse split of their stock that would allow them to list on a National Exchange, despite being approved by shareholders.
ACT has further enhanced their chances of success by amending their patient protocol to allow for the treatment of patients with better vision. Their hope is that many of these patients will be younger, have fewer complications unrelated to the treatment and be more capable to achieve significant results. If ACT keeps achieving positive results, the future of stem cell research will be a boon for investors. At around $.08, ACT currently remains one penny stock with great promise despite still having so much more to prove.
Any position on ACT is a high risk investment which should be considered with a very conservative approach."